JP4009772B2 - Adsorbent and extracorporeal circulation column for transforming growth factor beta - Google Patents

Adsorbent and extracorporeal circulation column for transforming growth factor beta Download PDF

Info

Publication number
JP4009772B2
JP4009772B2 JP2001307333A JP2001307333A JP4009772B2 JP 4009772 B2 JP4009772 B2 JP 4009772B2 JP 2001307333 A JP2001307333 A JP 2001307333A JP 2001307333 A JP2001307333 A JP 2001307333A JP 4009772 B2 JP4009772 B2 JP 4009772B2
Authority
JP
Japan
Prior art keywords
growth factor
factor beta
transforming growth
adsorbent
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001307333A
Other languages
Japanese (ja)
Other versions
JP2003111834A (en
JP2003111834A5 (en
Inventor
和雄 寺本
敏雄 吉岡
武雄 松名瀬
幸二 渡辺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Priority to JP2001307333A priority Critical patent/JP4009772B2/en
Publication of JP2003111834A publication Critical patent/JP2003111834A/en
Publication of JP2003111834A5 publication Critical patent/JP2003111834A5/ja
Application granted granted Critical
Publication of JP4009772B2 publication Critical patent/JP4009772B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Description

【0001】
【発明の属する技術分野】
本発明は、血液中に過剰に存在すれば免疫の大幅な低下を招き、癌の形成が促進される免疫抑制性蛋白質である分子量が25000程度のTGFβに他の蛋白質が結合したTGFβを除去するための吸着材および体外循環カラムに関する。
【0002】
【従来の技術】
医学の発達した今日でも、依然として日本人の主な死亡原因の一つが癌である。その原因は患者には手術で取りきれない癌細胞が存在するためであり、その除去のため抗癌剤治療や放射線治療が行われてきた。しかし、これらは正常細胞をも傷害するため患者の生命を維持しつつ癌細胞を完全に除去することができない。一方、最近、患者の免疫力を高めて、患者自身の白血球で癌を排除しようとする細胞療法が盛んに試みられる様になった。最も有望なものとして、患者の樹状細胞を体外で癌抗原刺激した後、患者に戻し、癌特異的キラー細胞(CTL)を誘導して治療しようとする樹状細胞輸注療法がある。しかし、健康な動物の血液からはCTLを誘導できても癌末期の担癌動物からは誘導できないことが多い。また、動物実験では好成績を得ても臨床では目に見えた効果が出ないことが殆どである。この理由として患者の血中には免疫を抑制する物質が存在するためと考えられる。その免疫抑制物質の代表的なものがトランスフォーミング・グロウス・ファクター・ベータ(TGFβ)や免疫抑制酸性蛋白である。この物質がCTLの誘導や機能発現を阻害していると考えられる。TGFβは、健康な人の血液中にも存在する蛋白質で免疫作用を調整する重要な物質であるが、癌の進行に伴って異常に増え、癌細胞の増殖を助けていると考えられる。TGFβは単独では分子量25000程度の蛋白質であるが、血中では他の蛋白質と結合して10万前後の分子量で存在するため、従来の吸着材では吸着除去が困難な物質である。従って、癌患者の血液中から異常に増えたTGFβを効率よく除去できる吸着材は知られていない。また、免疫抑制酸性蛋白は分子量5万程度の蛋白質で、癌の悪性度のマーカーとして臨床で利用されているが、免疫を抑制すると言われている。活性炭カラムでの除去も試みられたが、吸着能力が不十分だったためか治療効果が明確でなかった。また、活性炭は粉が出やすいので、直接、血液と接触する用途には向かない。これら免疫抑制物質の除去には、理論上、血漿交換も有効であるが、感染の危険が避けがたい本質的な欠点がある。
【0003】
【発明が解決しようとする課題】
本発明は、かかる従来技術の問題点に鑑み、一般的に普及可能であり、体液中から、直接、血液中において分子量が25000程度のTGFβに他の蛋白質が結合したTGFβを高い効率で選択的に吸着し、かつ、安全に体外循環できる、血液中において分子量が25000程度のTGFβに他の蛋白質が結合したTGFβの吸着材を提供し、ひいては癌の治療に役立てることを目的とする。
【0004】
【課題を解決するための手段】
すなわち本発明は、比表面積が1グラム当たり0.1平方メートル以上であり、不溶性担体に親水性アミン残基を結合してなる、血液中において分子量が25000程度のTGFβに他の蛋白質が結合したTGFβを吸着することを特徴とする免疫抑制性蛋白質の吸着材である。
【0005】
また本発明は、上記の吸着材を充填した体外循環カラムである。
【0006】
【発明の実施の形態】
続いて、本発明についてさらに詳細に説明する。
【0007】
本発明で用いる水不溶性担体としては、水に不溶で、親水性アミンを固定化できるものであれば良く、特に制限はない。
水不溶性担体の具体例としてはポリスチレンで代表されるポリ(芳香族ビニル化合物)、ポリ(p−フェニレンエーテルスルホン)や−{(p−C6 4 )−C(CH32−(p−C6 4 )−O−(p−C6 4 )−SO2 −(p−C6 4 )−O−}n−(以下ユーデルポリスルホンと略記する)などで代表されるポリスルホン系重合体、ポリエーテルイミド、ポリイミド、ポリアミド、ポリエーテル、ポリフェニレンサルファイドなどで、かつ、親水性アミンを固定化できるものがあげられる。親水性アミンを固定化するための反応性官能基としては、ハロメチル基、ハロアセチル基、ハロアセトアミドメチル基、ハロゲン化アルキル基などの活性ハロゲン基、エポキサイド基、カルボキシル基、イソシアン酸基、チオイソシアン酸基、酸無水物基などをあげることができるが、とりわけ、活性ハロゲン基、中でも、ハロアセチル基は、製造が容易な上に、反応性が適度に高く、親水性アミンの固定化反応が温和な条件で遂行できると共に、この際生じる共有結合が化学的に安定なので好ましい。さらに具体的な例としては、クロルアセトアミドメチルポリスチレン、クロルアセトアミドメチル化したユーデル・ポリスルホン、クロルアセトアミドメチル化したポリエーテルイミドなどがあげられる。さらに、これらのポリマーは有機溶媒に対し可溶であると、成型しやすい利点がある。
【0008】
本発明で言う親水性アミン残基とは、単独では水に溶解もしくは水を溶解するアミンがポリマーに化学的に結合した状態のものを意味する。さらに、親水性アミン残基の親水性アミンとしては、炭素数で言うと、窒素原子1個当たり炭素数18以下であるものがこれに相当する。
【0009】
さらに、親水性アミンの中でも、窒素原子1個当たり炭素数3以上18以下、とりわけ、4以上14以下のアルキル基を持つ第3級アミンから得られる第4アンモニウム基を結合したものが優れている。そのような第3級アミンの具体例としては、トリメチルアミン、トリエチルアミン、N、N−ジメチルヘキシルアミン、N、N−ジメチルオクチルアミン、N,N−ジメチルラウリルアミン、N−メチル−N−エチル−ヘキシルアミンなどがあげられる。さらに、親水性アミンを構成するアルキル基が親水性基である水酸基やエーテル基を含むもの、例えば、N,N−ジメチル−6−ヒドロキシヘキシルアミンやN,N−ジメチル−4−メトキシブチルアミン等も親水性アミンとして好ましく用いうる。
【0010】
本発明における親水性アミン残基の結合の密度は、水不溶性重合体の化学構造および用途により異なるが、少なすぎるとその機能が発現しない傾向にあり、一方、多すぎると、固定化後の重合体の物理的強度が悪くなり、吸着材としての機能も下がる傾向にあるので、該密度は水不溶性重合体の繰り返し単位あたり0.01〜2.0モル、より好ましくは0.1〜1.0モルが良い。
【0011】
本発明の吸着材の表面積は吸着材1グラム当たり0.1平方メートル以上であることが重要であり、より好ましくは、1平方メートル以上である。ただし無限に大きくはできないので、実際上、限界があり、100平方メートル以下が好ましい。この表面積は窒素ガス吸着法(BET法)で求めることができる。
【0012】
本発明の吸着材は、親水性アミン残基を結合した水不溶性重合体を膜、繊維、粒状物またはこれらの組み立て品に成型するか、あるいは親水性アミン残基を結合した水不溶性重合体を、膜、繊維、粒状物のいずれかの基材に被覆せしめるか、あるいは水不溶性重合体の膜、繊維等の成型品に親水性アミンを結合させるか等により得ることができる。
【0013】
親水性アミン残基を結合した水不溶性担体の成型品の製造には、水不溶性重合体の成型品に親水性アミンの溶液を接触させる不均一系反応の方法と水不溶性重合体の溶液と親水性アミンの溶液を混合して反応させた後、成型する均一系反応の方法とがある。不均一系反応の方法の一例としては、クロルアセトアミドメチル化ポリスルホンの繊維または中空糸などの成型品をジメチルヘキシルアミンやポリアルキレンイミン等のイソプロパノール溶液中に浸し、0〜100℃の温度で反応させることにより、容易に達成される。均一系反応による方法の一例を述べると、クロルアセトアミドメチル化ポリスルホンの溶液中に対応したポリアミンを加えて、0〜100℃の温度で反応させることにより、達成される。その量には特に制限はないが、可溶性のポリマーを得るためにはハロアセトアミドメチル基に対し1倍モル以上用いるのが望ましい。とりわけ、ポリアミンの場合は、可溶性の重合体を得るためには親水性アミンを大過剰用いるのが好ましい。
【0014】
また、反応溶媒としては、水、メタノール、エタノール、イソプロパノール、ジメチルスルホキシド、N,N−ジメチルホルムアミド(DMF)などの極性の高い溶媒の方が反応が速く進む利点がある。不均一系反応では、親水性アミンが溶ける溶媒であれば良く、特に制限はない。均一系で反応させる場合には、水不溶性担体と親水性アミンの両方が溶解する溶媒、具体的にはテトラヒドロフラン、ジメチルスルホキシド、N,N−ジメチルホルムアミド、N,N−ジメチルアセトアミド、N−メチルピロリドンなどが好ましく用いらる。また、成型品を表面処理する方法も可能で、そのためには水、メタノール、エタノールなどの、ポリスルホンを溶かさずに親水性アミンを溶かす溶媒が好ましく用いられる。
【0015】
本発明の吸着材ポリマーをポリエステル繊維、ナイロン繊維、ポリフェニレンサルファイド繊維などの成型品の表面にコーティングすると、簡単且つ安価に表面積の大きな高次の成型品が得られる利点がある。コーティングは、本発明の吸着材を塩化メチレンやテトラヒドロフランなどの低沸点溶媒に溶かしたものにナイロンの編み地や織物を浸したのち、溶媒を蒸発することにより容易に達成できる。また、N,N−ジメチルホルムアミドなどの溶媒に溶かしたものを水などのポリマーの貧溶媒に入れる湿式コーティング法も利用できる。コーティングされる成型品のポリマーはポリアミド、ポリウレタン、ポリイミド、ポリスルホン、ポリ塩化ビニル、ポリエステルなど、本発明吸着材ポリマーとの接着性の良いものであれば何でも良く、その種類には特に制限はないが、ナイロン、ポリエーテルイミドなどのアミド系のポリマーが接着性が特に良いので、好ましく用いられる。
【0016】
上記の成型や基材への被覆において、成型品や基材の形態に採用する繊維として、中空糸を用いることも好ましい。この場合、濾過の機能を具備した吸着材が作れるので、人工透析器として、あるいは、血漿分離器として使用しながら免疫抑制物質を除去できる利点がある。
【0017】
本発明の吸着材は血液中の分子量が25000程度のTGFβに他の蛋白質が結合したTGFβの除去の目的で、カラムに詰めた状態で、癌等の病気の体外循環治療に用いられる。本カラム作製は、綿状、筒編み状、フェルト状の本発明吸着材を、空隙容積が200mL程度以下になるようにして、適度の大きさの円筒形のカラムに詰めることで達成できる。また、本発明吸着材は輸血用血液、血清、血漿からの免疫抑制性蛋白質の除去の目的にも用いることができる。
【0018】
【実施例】
以下、実験例により本発明をさらに具体的に説明する。
【0019】
なお、本実施例中の評価方法は、以下に従った。
1.血液中の成分の分析
TGFβ1濃度はゼンザイム・テクネ社のヒトTGF−β1免疫分析キットを使用して求めた。また免疫抑制酸性蛋白の濃度は、三光純薬社製のラットIAPプレートを使用して求めた。アルブミン濃度はアルブミン分析キットであるアルブミンB−テストワコーで求めた。
【0020】
(水不溶性担体)
36島の海島複合繊維であって、島が更に芯鞘複合によりなるものを次の成分を用いて、紡糸速度800m/分、延伸倍率3倍の製糸条件で得た。
島の芯成分;ポリプロピレン
島の鞘成分;ポリスチレン90%、ポリプロピレン10%
海成分;5−ナトリウムスルホイソフタル酸を3%共重合したポリエチレンテレフタレート
複合比率;芯:鞘:海=40:40:20。
この海成分を熱苛性ソーダ水溶液で溶解し、芯鞘型のポリプロピレン補強ポリスチレン繊維として、直径4μmの原糸1を得た。
【0021】
また、吐出量や延伸倍率を適宜変更し、同様にして直径10μmの原糸2、直径50μmの原糸3を得た。
【0022】
(中間体)
ニトロベンゼン600mLと硫酸390mLの混合溶液にパラホルムアルデヒド3gを20℃で溶解した後、0℃に冷却し、75.9gのN−メチロール−α−クロルアセトアミドを加えて、5℃以下で溶解した。これに10gの上記で調製した原糸1を浸し、室温で2時間静置した。その後、繊維を取りだし、大過剰の冷メタノール中に入れ、洗浄した。繊維をメタノールで良く洗った後、水洗し、乾燥して、15.0gのα−クロルアセトアミドメチル化ポリスチレン繊維(中間体1)を得た。中間体1は比較例1としても用いた。また、10gの原糸2および10gの原糸3を同様に処理して、中間体2(収量14.4g)および中間体3(収量12.5g)を得た。
【0023】
(親水性アミンの不均一系反応による固定)
N,N−ジメチルヘキシルアミン50gとヨウ化カリウム8gを360mLのDMFに溶かした溶液に5gの中間体1を浸し、85℃のバス中で3時間加熱した。繊維を1モル/L濃度の食塩水に浸漬した後、水洗し、真空乾燥して、7.3gのジメチルヘキシルアンモニウム化繊維(実施例1)を得た。
【0024】
また、N,N−ジメチルオクチルアミン50gとヨウ化カリウム8gを360mLのDMFに溶かした溶液に5gの中間体1を浸し、85℃のバス中で3時間加熱した。繊維をイソプロパノールで洗浄後、1モル/L濃度の食塩水に浸漬した後、水洗し、真空乾燥して、8.3gのジメチルオクチルアンモニウム化繊維(実施例2)を得た。
【0025】
また、N,N−ジメチルラウリルアミン50gとヨウ化カリウム8gを360mLのDMFに溶かした溶液に5gの中間体1を浸し、85℃のバス中で3時間加熱した。繊維をイソプロパノールで洗浄後、1モル/L濃度の食塩水に浸漬した後、水洗し、真空乾燥して、9.3gのジメチルラウリルアンモニウム化繊維(実施例3)を得た。また、中間体2および中間体3を同様に処理して、それぞれ実施例4(比表面積1.4m2/g)および比較例4(比表面積0.04m2/g)を得た。
【0026】
(非親水性アミンの不均一系反応による固定)
また、非親水性アミンとして、ステアリルアミン50gを360mLのエタノールに溶かした溶液に5gの中間体1を浸し、85℃のバス中で3時間加熱した。繊維をイソプロパノールで洗浄後、水洗し、真空乾燥して、7.2gのステアリルアミノ化繊維(比較例2)を得た。
【0027】
(スルホン化繊維)
また、パラホルムアルデヒド500mgを溶解した硫酸50mLに、5gの原糸1を浸し、95℃で1時間加熱した後、水洗、1モル/L濃度の食塩水での洗浄、水洗、乾燥を逐次行って、7.3gのスルホン化繊維(比較例3)を得た。
【0028】
(親水性アミン結合ポリマーの合成とコーティング)
ニトロベンゼン16mLと硫酸32mLの混合溶液を0℃に冷却後、4.2gのN−メチロール−α−クロルアセトアミドを加えて、溶解し、これを、10℃のユーデルポリスルホンP3500の3Lのニトロベンゼン溶液(300g/3L)に、良く撹拌しながら加えた。さらに、室温で3時間撹拌した。その後、反応混合物を大過剰の冷メタノール中に入れ、ポリマーを沈殿させた。沈殿をメタノールで良く洗った後、乾燥し、さらに、ジメチルホルムアミド/メタノールから再沈殿して、303gのα−クロルアセトアミドメチル化ポリスルホン(置換率:0.05;重合体C)を得た。
【0029】
ポリエチレンイミン(平均分子量10000:和光純薬)60gを300mLのDMFに溶かした溶液と30gの重合体Cを含む300mLのDMF溶液と混合し、室温で48時間撹拌した。反応混合物を大過剰の飽和食塩水に加え、沈殿したポリマーをろ取した。ポリマーを水洗後、乾燥し、さらに、ジメチルホルムアミド/メタノールから再沈殿して、27gのN−アルキル化ポリアルキレンイミン固定化ポリスルホン(重合体D)を調製した。
【0030】
上記重合体Dを5g含む塩化メチレン250mLの溶液に、単糸の直径が3.5μmのポリエチレンテレフタレート繊維の綿20gを浸し、20時間後に綿を取り出し、液を切って風乾し、21gのコーティング綿(実施例5)を得た。
【0031】
(非イオン性官能基の吸着材)
酢酸セルロース5gを塩化メチレン250mlに溶かし、単糸の直径が3.5μmのポリエチレンテレフタレート繊維の綿20gを浸し、20時間後に綿を取り出し、液を切って風乾し、21gのコーティング綿(比較例5)を得た。
【0032】
(吸着能の評価)
8週令のHOS:Donryuラット(雄)の背部皮下にYS細胞(東北大学加齢研究所提供)2×108個接種して調製した担癌ラット5匹から血液を採取し、血清30mLを調製した。その血清1mLに吸着材50mgを入れ、37℃で4時間振とうした。上清中の各蛋白質濃度を測定して、表1の結果を得た。
【0033】
【表1】

Figure 0004009772
【0034】
表1の比較例1では比表面積が大きいにも拘わらず、親水性アミノ基のリガンドがないため吸着性がない。比較例2は親水性でないアミノ基のリガンドのため吸着能が無い。比較例3からスルホン酸基のリガンドは吸着性がないことが分かる。また、比較例4は親水性アミノ基のリガンドであるが、実施例3及び実施例4と異なり比表面積が低いため吸着能が殆ど無い。比較例5及び比較例6は比表面積は小さくないが、親水性アミノ基のリガンドがないため吸着能がない。これらの結果から、吸着には親水性アミンの官能基が必要であること、比表面積が0.04平方メートルでは吸着能が低いことが分かる。また、親水性アミンの中でも、窒素原子1個当たりの炭素数が14のものより10および8のものの吸着能が大きいことが分かる。
【0035】
【発明の効果】
本発明により、免疫抑制性物質を効率よく吸着除去することが可能となり、癌の患者の治療に有用である。[0001]
BACKGROUND OF THE INVENTION
The present invention removes TGFβ in which other proteins are bound to TGFβ having a molecular weight of about 25,000, which is an immunosuppressive protein that promotes the formation of cancer if it is excessively present in the blood. The present invention relates to an adsorbent and an extracorporeal circulation column.
[0002]
[Prior art]
Even today, with the development of medicine, cancer is still one of the main causes of death in Japan. The cause is that there are cancer cells that cannot be removed by surgery in patients, and anticancer drug treatment and radiation therapy have been performed to remove them. However, since these also damage normal cells, cancer cells cannot be completely removed while maintaining the patient's life. On the other hand, recently, cell therapy has been actively tried to improve the immunity of patients and eliminate cancer with their own white blood cells. The most promising is dendritic cell infusion therapy in which a patient's dendritic cells are stimulated with cancer antigens outside the body and then returned to the patient to induce and treat cancer-specific killer cells (CTLs). However, in many cases, CTL can be induced from the blood of healthy animals, but cannot be induced from cancer-bearing animals at the end of cancer. In animal experiments, even if good results are obtained, there is almost no visible effect in clinical practice. This may be because a substance that suppresses immunity exists in the blood of the patient. Representative examples of such immunosuppressive substances are transforming growth factor beta (TGFβ) and immunosuppressive acidic proteins. This substance is thought to inhibit CTL induction and functional expression. TGFβ is an important substance that regulates immunity with a protein that is also present in the blood of a healthy person, but is thought to increase abnormally as cancer progresses and to help cancer cells grow. TGFβ alone is a protein having a molecular weight of about 25,000. However, TGFβ is a substance that is difficult to adsorb and remove with conventional adsorbents because it binds to other proteins in blood and has a molecular weight of around 100,000. Therefore, no adsorbent is known that can efficiently remove abnormally increased TGFβ from the blood of cancer patients. Immunosuppressive acidic protein is a protein having a molecular weight of about 50,000 and is clinically used as a marker of cancer malignancy, but is said to suppress immunity. Attempts were made to remove it with an activated carbon column, but the therapeutic effect was not clear due to insufficient adsorption capacity. In addition, activated carbon is easy to produce powder, so it is not suitable for use in direct contact with blood. The removal of these immunosuppressive substances is theoretically effective for plasma exchange, but has the inherent disadvantage that the risk of infection is unavoidable.
[0003]
[Problems to be solved by the invention]
The present invention is generally ubiquitous in view of the problems of the prior art, and can select TGFβ obtained by binding other proteins directly to TGFβ having a molecular weight of about 25,000 in blood directly from a body fluid with high efficiency. It is intended to provide an adsorbent for TGFβ, which can be adsorbed on the surface and can be safely circulated outside the body, and in which TGFβ having a molecular weight of about 25,000 in blood is bound to other proteins, and thus useful for cancer treatment.
[0004]
[Means for Solving the Problems]
That is, the present invention has a specific surface area of more than 0.1 square meters per gram, formed by bonding a hydrophilic amine residue to an insoluble carrier, TGF [beta other protein molecular weight of about 25000 TGF [beta in the blood is bound It is an adsorbent for an immunosuppressive protein characterized by adsorbing.
[0005]
Moreover, this invention is an extracorporeal circulation column filled with said adsorption material.
[0006]
DETAILED DESCRIPTION OF THE INVENTION
Subsequently, the present invention will be described in more detail.
[0007]
The water-insoluble carrier used in the present invention is not particularly limited as long as it is insoluble in water and can immobilize a hydrophilic amine.
Specific examples of the water-insoluble carrier include poly (aromatic vinyl compounds) represented by polystyrene, poly (p-phenylene ether sulfone) and-{(p-C 6 H 4 ) -C (CH 3 ) 2- (p -C 6 H 4) -O- (p -C 6 H 4) -SO 2 - (p-C 6 H 4) -O-} n - ( hereinafter abbreviated as U del polysulfone) polysulfone represented by like Examples thereof include polymers, polyetherimides, polyimides, polyamides, polyethers, polyphenylene sulfides, and the like that can immobilize hydrophilic amines. Reactive functional groups for immobilizing hydrophilic amines include active halogen groups such as halomethyl, haloacetyl, haloacetamidomethyl, and halogenated alkyl groups, epoxide groups, carboxyl groups, isocyanate groups, and thioisocyanate Groups, acid anhydride groups, and the like. In particular, active halogen groups, especially haloacetyl groups, are easy to produce, have moderately high reactivity, and have a mild hydrophilic amine immobilization reaction. It is preferable because it can be carried out under conditions and the covalent bond formed at this time is chemically stable. More specific examples include chloroacetamidomethyl polystyrene, chloracetamidomethylated Udel polysulfone, chloroacetamidomethylated polyetherimide, and the like. Furthermore, when these polymers are soluble in an organic solvent, there is an advantage that they are easy to mold.
[0008]
The hydrophilic amine residue as used in the field of this invention means the thing of the state which the amine which melt | dissolves in water alone or dissolves water chemically couple | bonded with the polymer. Furthermore, as the hydrophilic amine of the hydrophilic amine residue, in terms of the number of carbon atoms, one having 18 or less carbon atoms per nitrogen atom corresponds to this.
[0009]
Furthermore, among hydrophilic amines, those bonded with a quaternary ammonium group obtained from a tertiary amine having an alkyl group having 3 to 18 carbon atoms, particularly 4 to 14 carbon atoms per nitrogen atom are excellent. . Specific examples of such tertiary amines include trimethylamine, triethylamine, N, N-dimethylhexylamine, N, N-dimethyloctylamine, N, N-dimethyllaurylamine, N-methyl-N-ethyl-hexyl. Examples include amines. Further, those containing a hydroxyl group or ether group in which the alkyl group constituting the hydrophilic amine is a hydrophilic group, such as N, N-dimethyl-6-hydroxyhexylamine and N, N-dimethyl-4-methoxybutylamine are also included. It can be preferably used as a hydrophilic amine.
[0010]
The bonding density of hydrophilic amine residues in the present invention varies depending on the chemical structure and use of the water-insoluble polymer. However, if the amount is too small, the function tends not to be expressed. Since the physical strength of the coalescence deteriorates and the function as an adsorbent tends to decrease, the density is 0.01 to 2.0 mol, more preferably 0.1 to 1. mol per repeating unit of the water-insoluble polymer. 0 mole is good.
[0011]
It is important that the surface area of the adsorbent of the present invention is 0.1 square meter or more per gram of adsorbent, more preferably 1 square meter or more. However, since it cannot be infinitely large, there is a practical limit, and 100 square meters or less is preferable. This surface area can be determined by a nitrogen gas adsorption method (BET method).
[0012]
The adsorbent of the present invention is obtained by molding a water-insoluble polymer bonded with a hydrophilic amine residue into a film, a fiber, a granular material or an assembly thereof, or a water-insoluble polymer bonded with a hydrophilic amine residue. It can be obtained by coating a substrate of any one of a membrane, a fiber and a granular material, or by bonding a hydrophilic amine to a molded product such as a membrane or fiber of a water-insoluble polymer.
[0013]
For the production of a water-insoluble carrier molded product bonded with a hydrophilic amine residue, a heterogeneous reaction method in which a hydrophilic amine solution is brought into contact with a water-insoluble polymer molded product, and the water-insoluble polymer solution and the hydrophilic There is a homogeneous reaction method in which a solution of a reactive amine is mixed and reacted and then molded. As an example of a heterogeneous reaction method, a molded product such as a fiber or hollow fiber of chloroacetamidomethylated polysulfone is immersed in an isopropanol solution such as dimethylhexylamine or polyalkyleneimine and reacted at a temperature of 0 to 100 ° C. This is easily achieved. An example of the method by homogeneous reaction is achieved by adding the corresponding polyamine to a solution of chloroacetamidomethylated polysulfone and reacting at a temperature of 0 to 100 ° C. The amount is not particularly limited, but it is desirable to use at least 1 mole per mole of haloacetamidomethyl groups to obtain a soluble polymer. In particular, in the case of polyamine, it is preferable to use a large excess of hydrophilic amine in order to obtain a soluble polymer.
[0014]
As the reaction solvent, a solvent having a high polarity such as water, methanol, ethanol, isopropanol, dimethyl sulfoxide, N, N-dimethylformamide (DMF) has an advantage that the reaction proceeds faster. The heterogeneous reaction is not particularly limited as long as it is a solvent in which the hydrophilic amine is soluble. When the reaction is carried out in a homogeneous system, a solvent in which both the water-insoluble carrier and the hydrophilic amine are dissolved, specifically tetrahydrofuran, dimethyl sulfoxide, N, N-dimethylformamide, N, N-dimethylacetamide, N-methylpyrrolidone Etc. are preferably used. In addition, a method of surface-treating a molded product is also possible, and for this purpose, a solvent that dissolves a hydrophilic amine without dissolving polysulfone, such as water, methanol, and ethanol, is preferably used.
[0015]
When the adsorbent polymer of the present invention is coated on the surface of a molded product such as polyester fiber, nylon fiber, polyphenylene sulfide fiber, etc., there is an advantage that a high-order molded product having a large surface area can be obtained easily and inexpensively. Coating can be easily achieved by immersing a nylon knitted fabric or woven fabric in the adsorbent of the present invention dissolved in a low-boiling solvent such as methylene chloride or tetrahydrofuran and evaporating the solvent. Further, a wet coating method in which a solution dissolved in a solvent such as N, N-dimethylformamide is put into a poor solvent for a polymer such as water can also be used. The polymer of the molded article to be coated may be any polyamide, polyurethane, polyimide, polysulfone, polyvinyl chloride, polyester, etc., as long as it has good adhesion to the adsorbent polymer of the present invention, and there is no particular limitation on the type. An amide polymer such as nylon or polyetherimide is preferably used because of its particularly good adhesion.
[0016]
In the above molding and coating on the base material, it is also preferable to use a hollow fiber as a fiber to be employed in the form of the molded product or base material. In this case, since an adsorbent having a filtration function can be produced, there is an advantage that an immunosuppressive substance can be removed while being used as an artificial dialyzer or a plasma separator.
[0017]
Adsorbent of the present invention for the purpose of removal of TGF [beta bound by other proteins in the molecular weight of about 25000 TGF [beta in the blood, while packed in a column, employed in extracorporeal circulation treatment of cancer such diseases. This column can be produced by packing the adsorbent of the present invention in the form of cotton, cylinder, or felt into a cylindrical column having an appropriate size so that the void volume is about 200 mL or less. The adsorbent of the present invention can also be used for the purpose of removing immunosuppressive proteins from blood for transfusion, serum, and plasma.
[0018]
【Example】
Hereinafter, the present invention will be described more specifically by experimental examples.
[0019]
In addition, the evaluation method in a present Example followed the following.
1. Analysis of components in blood TGFβ1 concentration was determined using a human TGF-β1 immunoassay kit from Zenzyme Techne. The concentration of the immunosuppressive acidic protein was determined using a rat IAP plate manufactured by Sanko Junyaku Co., Ltd. The albumin concentration was determined by albumin B-Test Wako, which is an albumin analysis kit.
[0020]
(Water-insoluble carrier)
Thirty-six sea-island composite fibers, each of which is made of a core-sheath composite, were obtained using the following components under the spinning conditions of a spinning speed of 800 m / min and a draw ratio of 3 times.
Island core component; Polypropylene island sheath component: 90% polystyrene, 10% polypropylene
Sea component; Polyethylene terephthalate composite ratio obtained by copolymerization of 3% of 5-sodium sulfoisophthalic acid; Core: sheath: sea = 40: 40: 20.
This sea component was dissolved in a hot caustic soda aqueous solution to obtain a raw yarn 1 having a diameter of 4 μm as a core-sheath type polypropylene reinforced polystyrene fiber.
[0021]
Further, the discharge amount and the draw ratio were appropriately changed, and similarly, a raw yarn 2 having a diameter of 10 μm and a raw yarn 3 having a diameter of 50 μm were obtained.
[0022]
(Intermediate)
After 3 g of paraformaldehyde was dissolved at 20 ° C. in a mixed solution of 600 mL of nitrobenzene and 390 mL of sulfuric acid, the solution was cooled to 0 ° C., and 75.9 g of N-methylol-α-chloroacetamide was added and dissolved at 5 ° C. or lower. 10 g of the original yarn 1 prepared above was soaked in this, and allowed to stand at room temperature for 2 hours. Thereafter, the fiber was taken out and placed in a large excess of cold methanol for washing. The fiber was thoroughly washed with methanol, washed with water, and dried to obtain 15.0 g of α-chloroacetamidomethylated polystyrene fiber (intermediate 1). Intermediate 1 was also used as Comparative Example 1. Further, 10 g of raw yarn 2 and 10 g of raw yarn 3 were treated in the same manner to obtain Intermediate 2 (yield 14.4 g) and Intermediate 3 (yield 12.5 g).
[0023]
(Fixation by heterogeneous reaction of hydrophilic amine)
5 g of Intermediate 1 was immersed in a solution of 50 g of N, N-dimethylhexylamine and 8 g of potassium iodide in 360 mL of DMF, and heated in a 85 ° C. bath for 3 hours. The fiber was immersed in a 1 mol / L saline solution, then washed with water and vacuum dried to obtain 7.3 g of dimethylhexylammonium-modified fiber (Example 1).
[0024]
Further, 5 g of Intermediate 1 was immersed in a solution of 50 g of N, N-dimethyloctylamine and 8 g of potassium iodide in 360 mL of DMF, and heated in a bath at 85 ° C. for 3 hours. The fiber was washed with isopropanol, immersed in a 1 mol / L saline solution, washed with water, and dried under vacuum to obtain 8.3 g of dimethyloctylammonium-containing fiber (Example 2).
[0025]
Further, 5 g of Intermediate 1 was immersed in a solution of 50 g of N, N-dimethyllaurylamine and 8 g of potassium iodide in 360 mL of DMF, and heated in a 85 ° C. bath for 3 hours. The fiber was washed with isopropanol, immersed in a 1 mol / L saline solution, washed with water, and dried under vacuum to obtain 9.3 g of dimethyllauryl ammoniumated fiber (Example 3). Moreover, the intermediate body 2 and the intermediate body 3 were processed similarly, and Example 4 (specific surface area 1.4m < 2 > / g) and the comparative example 4 (specific surface area 0.04m < 2 > / g) were obtained, respectively.
[0026]
(Immobilization of non-hydrophilic amine by heterogeneous reaction)
Further, as a non-hydrophilic amine, 5 g of the intermediate 1 was immersed in a solution of 50 g of stearylamine in 360 mL of ethanol, and heated in a bath at 85 ° C. for 3 hours. The fiber was washed with isopropanol, washed with water, and dried under vacuum to obtain 7.2 g of stearyl aminated fiber (Comparative Example 2).
[0027]
(Sulfonated fiber)
In addition, 5 g of the original yarn 1 is immersed in 50 mL of sulfuric acid in which 500 mg of paraformaldehyde is dissolved, heated at 95 ° C. for 1 hour, washed with water, washed with 1 mol / L saline solution, washed with water, and dried successively. 7.3 g of sulfonated fiber (Comparative Example 3) was obtained.
[0028]
(Synthesis and coating of hydrophilic amine bond polymer)
After cooling a mixed solution of 16 mL of nitrobenzene and 32 mL of sulfuric acid to 0 ° C., 4.2 g of N-methylol-α-chloroacetamide was added and dissolved, and this was dissolved in a 3 L nitrobenzene solution of Eudelpolysulfone P3500 at 10 ° C. 300 g / 3 L) with good stirring. Furthermore, it stirred at room temperature for 3 hours. The reaction mixture was then placed in a large excess of cold methanol to precipitate the polymer. The precipitate was washed well with methanol, dried, and reprecipitated from dimethylformamide / methanol to obtain 303 g of α-chloroacetamidomethylated polysulfone (substitution rate: 0.05; polymer C).
[0029]
A solution obtained by dissolving 60 g of polyethyleneimine (average molecular weight 10,000: Wako Pure Chemical Industries, Ltd.) in 300 mL of DMF and 300 mL of DMF solution containing 30 g of Polymer C were mixed and stirred at room temperature for 48 hours. The reaction mixture was added to a large excess of saturated brine, and the precipitated polymer was collected by filtration. The polymer was washed with water, dried, and reprecipitated from dimethylformamide / methanol to prepare 27 g of N-alkylated polyalkylenimine-immobilized polysulfone (Polymer D).
[0030]
20 g of polyethylene terephthalate fiber having a single yarn diameter of 3.5 μm is dipped in 250 mL of methylene chloride containing 5 g of the above polymer D. After 20 hours, the cotton is taken out, drained and air-dried, and 21 g of coated cotton. (Example 5) was obtained.
[0031]
(Nonionic functional group adsorbent)
Dissolve 5 g of cellulose acetate in 250 ml of methylene chloride, soak 20 g of polyethylene terephthalate fiber with a single yarn diameter of 3.5 μm, take out the cotton after 20 hours, drain the solution, air dry, and 21 g of coated cotton (Comparative Example 5 )
[0032]
(Evaluation of adsorption capacity)
Blood was collected from 5 cancer-bearing rats prepared by inoculating 2 × 10 8 YS cells (provided by Tohoku University Aging Research Institute) subcutaneously in the back of 8-week-old HOS: Donryu rats (male). Prepared. 50 mL of an adsorbent was added to 1 mL of the serum and shaken at 37 ° C. for 4 hours. Each protein concentration in the supernatant was measured, and the results shown in Table 1 were obtained.
[0033]
[Table 1]
Figure 0004009772
[0034]
Although Comparative Example 1 in Table 1 has a large specific surface area, it has no adsorptivity because there is no hydrophilic amino group ligand. Comparative Example 2 has no adsorptive capacity due to a non-hydrophilic amino group ligand. It can be seen from Comparative Example 3 that the sulfonic acid group ligand has no adsorptivity. Comparative Example 4 is a hydrophilic amino group ligand, but unlike Examples 3 and 4, it has almost no adsorptive capacity because of its low specific surface area. In Comparative Examples 5 and 6, the specific surface area is not small, but there is no adsorption ability because there is no hydrophilic amino group ligand. From these results, it is understood that a functional group of hydrophilic amine is necessary for adsorption, and that the adsorption capacity is low when the specific surface area is 0.04 square meters. It can also be seen that among hydrophilic amines, those having 10 and 8 carbon atoms per nitrogen atom have a higher adsorption capacity than 14 carbon atoms.
[0035]
【The invention's effect】
According to the present invention, an immunosuppressive substance can be efficiently adsorbed and removed, which is useful for the treatment of cancer patients.

Claims (8)

比表面積が1グラム当たり0.1平方メートル以上であり、水不溶性担体に窒素原子1個当たり炭素数3以上18以下である第4級アンモニウム基を結合してなることを特徴とする分子量が25000程度のトランスフォーミング・グロウス・ファクター・ベータに他の蛋白質が結合したトランスフォーミング・グロウス・ファクター・ベータの吸着材。The specific surface area is 0.1 square meter or more per gram, and a molecular weight of about 25,000 is formed by binding a quaternary ammonium group having 3 to 18 carbon atoms per nitrogen atom to a water-insoluble support. An adsorbent for transforming growth factor beta, in which other proteins are bound to transforming growth factor beta. 水不溶性担体がポリスルホン系重合体である請求項記載の分子量が25000程度のトランスフォーミング・グロウス・ファクター・ベータに他の蛋白質が結合したトランスフォーミング・グロウス・ファクター・ベータの吸着材。Transforming Growth Growth Factor beta adsorbent claim 1 molecular weight 25,000 about Transforming Growth Growth Factor Beta other proteins described bonded water-insoluble carrier is a polysulfone-based polymer. 水不溶性重合体がポリ(芳香族ビニル化合物)である請求項記載の分子量が25000程度のトランスフォーミング・グロウス・ファクター・ベータに他の蛋白質が結合したトランスフォーミング・グロウス・ファクター・ベータの吸着材。Water-insoluble polymer is poly (aromatic vinyl compound) in a claim 1 Transforming Growth Growth Factor beta adsorbent molecular weight other protein Transforming Growth Growth Factor Beta of about 25,000 is bonded according . 窒素原子1個当たり炭素数3以上18以下である第4級アンモニウム基を結合した水不溶性重合体を膜、繊維、粒状物またはこれらの組み立て品に成型した請求項1〜のいずれかに記載の分子量が25000程度のトランスフォーミング・グロウス・ファクター・ベータに他の蛋白質が結合したトランスフォーミング・グロウス・ファクター・ベータの吸着材。 Quaternary ammonium groups bound water insoluble polymer membrane nitrogen per atom carbon number of 3 to 18 or less, fibers, granules or according to any one of claims 1 to 3 was molded into these assembly An adsorbent for transforming growth factor beta, in which other proteins are bound to transforming growth factor beta having a molecular weight of about 25,000. 窒素原子1個当たり炭素数3以上18以下である第4級アンモニウム基を結合した水不溶性重合体を、膜、繊維、粒状物のいずれかの表面に被覆せしめた請求項1〜のいずれかに記載の分子量が25000程度のトランスフォーミング・グロウス・ファクター・ベータに他の蛋白質が結合したトランスフォーミング・グロウス・ファクター・ベータの吸着材。 Quaternary water-insoluble polymer an ammonium group bonded at most one nitrogen atom per carbon number of 3 to 18, and film, fiber, claim 1-3 which allowed coated on either surface of the granules An adsorbent for transforming growth factor beta, in which another protein is bound to transforming growth factor beta having a molecular weight of about 25,000. 血液中において分子量が25000程度のトランスフォーミング・グロウス・ファクター・ベータに他の蛋白質が結合したトランスフォーミング・グロウス・ファクター・ベータに対する吸着能が吸着材1グラムあたり340ミリグラム以上であることを特徴とする請求項1〜のいずれかに記載の分子量が25000程度のトランスフォーミング・グロウス・ファクター・ベータに他の蛋白質が結合したトランスフォーミング・グロウス・ファクター・ベータの吸着材。It is characterized in that the adsorbing ability to transforming growth factor beta in which other proteins are bound to transforming growth factor beta having a molecular weight of about 25,000 in blood is 340 mg or more per gram of adsorbent. An adsorbent for transforming growth factor beta obtained by binding another protein to the transforming growth factor beta having a molecular weight of about 25,000 according to any one of claims 1 to 5 . 請求項1〜のいずれかに記載の分子量が25000程度のトランスフォーミング・グロウス・ファクター・ベータに他の蛋白質が結合したトランスフォーミング・グロウス・ファクター・ベータの吸着材を充填した体外循環カラム。An extracorporeal circulation column packed with a transforming growth factor beta adsorbent in which another protein is bound to the transforming growth factor beta having a molecular weight of about 25,000 according to any one of claims 1 to 6 . 請求項1〜のいずれかに記載の分子量が25000程度のトランスフォーミング・グロウス・ファクター・ベータに他の蛋白質が結合したトランスフォーミング・グロウス・ファクター・ベータの吸着材を充填した癌治療用体外循環カラム。An extracorporeal circulation for cancer treatment, which is filled with an adsorbent of transforming growth factor beta in which another protein is bound to transforming growth factor beta having a molecular weight of about 25,000 according to any one of claims 1 to 6. column.
JP2001307333A 2001-10-03 2001-10-03 Adsorbent and extracorporeal circulation column for transforming growth factor beta Expired - Lifetime JP4009772B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001307333A JP4009772B2 (en) 2001-10-03 2001-10-03 Adsorbent and extracorporeal circulation column for transforming growth factor beta

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001307333A JP4009772B2 (en) 2001-10-03 2001-10-03 Adsorbent and extracorporeal circulation column for transforming growth factor beta

Publications (3)

Publication Number Publication Date
JP2003111834A JP2003111834A (en) 2003-04-15
JP2003111834A5 JP2003111834A5 (en) 2005-03-03
JP4009772B2 true JP4009772B2 (en) 2007-11-21

Family

ID=19126810

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001307333A Expired - Lifetime JP4009772B2 (en) 2001-10-03 2001-10-03 Adsorbent and extracorporeal circulation column for transforming growth factor beta

Country Status (1)

Country Link
JP (1) JP4009772B2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106972A1 (en) 2005-03-31 2006-10-12 Toray Industries, Inc. Adsorbent and column for extracorporeal circulation
JP4983070B2 (en) * 2005-04-08 2012-07-25 東レ株式会社 Adsorbent and extracorporeal circulation column
JP5017996B2 (en) * 2006-01-30 2012-09-05 東レ株式会社 Leukocyte and cytokine adsorber
JP4997770B2 (en) * 2006-01-31 2012-08-08 東レ株式会社 Adsorber
JP2007260216A (en) * 2006-03-29 2007-10-11 Toray Ind Inc Adsorbent carrier and column for extracorporeal circulation
KR101398768B1 (en) 2006-09-29 2014-05-27 도레이 카부시키가이샤 Cell-adsorbing column
JP5341559B2 (en) * 2009-03-03 2013-11-13 和雄 寺本 Porous adsorbent
JP5916712B2 (en) 2011-03-29 2016-05-11 国立大学法人滋賀医科大学 Immunosuppressive cell collection material and immunosuppressive cell collection column

Also Published As

Publication number Publication date
JP2003111834A (en) 2003-04-15

Similar Documents

Publication Publication Date Title
US5456835A (en) Device and process for removing free hemoglobin from blood
JPH09508823A (en) Devices and processes for the removal of leukocytes and virus inactivating agents from blood.
JP4009772B2 (en) Adsorbent and extracorporeal circulation column for transforming growth factor beta
US8932590B2 (en) Method of adsorbing transforming growth factor β
JPH0516304B2 (en)
JP2006288571A (en) Adsorbent for cancer treatment and column for extracorporeal circulation
BR112020003093A2 (en) adsorption material for immunosuppressive leukocytes, and, adsorption column
JP5017996B2 (en) Leukocyte and cytokine adsorber
JP4182682B2 (en) Carcinoembryonic antigen adsorbent and extracorporeal circulation column
JP4200689B2 (en) Extracorporeal circulation column for cancer treatment
JP2004248950A (en) Adsorbing material for immunosuppressive substance and column for extracorporeal circulation
JP2777604B2 (en) Adsorbent for body fluid treatment
JP4032465B2 (en) Thrombogenic substance adsorbent and extracorporeal circulation column
JP2004073618A (en) Adsorbent and extracorporeal circulation column filled with the adsorbent
JP4779190B2 (en) Inflammatory disease treatment column
JP4453395B2 (en) Use of extracorporeal circulation column suitable for cancer treatment
US9982369B2 (en) Fiber and column for protein adsorption
JP2002035118A (en) Column for treating inflammatory disease
JP2002113097A (en) Adsorbent and in vitro circulation column
JP7459449B2 (en) Adsorption material for soluble tumor necrosis factor receptors
JP4505950B2 (en) Adsorbent and extracorporeal circulation column
JP3911815B2 (en) Polysulfone polymer, its production method and its use
CN109046282B (en) Adsorbent for removing endotoxin by hemoperfusion and water solution and preparation method thereof
JP2004129941A (en) Leukocyte selective removal filter
JPH0622623B2 (en) Material for removing endotoxin and method for removing endotoxin

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040330

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20060525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060606

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060804

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070130

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070329

A911 Transfer of reconsideration by examiner before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20070515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070619

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070702

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070807

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070820

R151 Written notification of patent or utility model registration

Ref document number: 4009772

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R151

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100914

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110914

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120914

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130914

Year of fee payment: 6